9月5日，据睿智医药消息，近日，复星医药联席总裁、全球研发中心CEO王兴利博士率研发团队到访睿 智医药科技股份有限公司上海总部，举行座谈交流。双方就生物医药研发领域的技术创新和新模态药物 的发展方向展开深入交流，进一步深化了双方合作共识。 ...

Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovative enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from a follower to a leader in innovation [2] Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit attributable to shareholders of 1.702 billion yuan, representing a year-on-year growth of 38.96% [2] - Revenue from innovative drugs exceeded 4.3 billion yuan, with a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [2] Innovation Strategy - The company has approved 4 innovative drugs (covering 5 indications) and 57 generic drugs during the reporting period, with 4 innovative drugs and 22 generic drugs submitted for market approval [3] - Fosun Pharma emphasizes the importance of innovation in drug development efficiency, speed to market, and commercialization [4] Global Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue [5] - The company has established a clinical operations team in the U.S. for the commercialization of innovative products and has set up regional distribution centers in emerging markets [5][6] Business Development - Fosun Pharma's innovative pipeline quality has improved, leading to increased business development activities and global licensing cooperation [6] - The company has achieved significant international recognition for its PD-1 monoclonal antibody, with approvals in over 30 countries and regions [6] Strategic Focus - The company is implementing a new A+H share equity incentive plan, with core performance indicators focusing on net profit and innovative drug revenue [4] - Fosun Pharma aims for a compound annual growth rate of approximately 20% in innovative drug revenue from 2025 to 2027 [4] Long-term Vision - The company is committed to its 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to enhance innovation speed and quality, as well as global reach [8]

● 本报记者 李梦扬 从仿制药起步到向高水平创新转型，从在中国市场扎根深耕到将视野拓展至全球舞台，回顾三十余年的 过往之路，复星医药与时代同频共振，持续聚焦创新转型和全球布局，成为中国医药产业从追随者向创 新引领者转变的生动缩影。 "创新已成为复星医药发展的核心引擎，我们要持续提升创新研发能力和研发效率。"复星医药董事长陈 玉卿接受中国证券报记者采访时表示，"公司针对未被满足的临床需求及核心治疗领域积极布局，聚焦 高价值管线的内部开发和外部引进，大力发展战略性产品，拓展全球市场机遇，优化资产配置，内部运 营进一步提质增效，以优化财务结构，夯实长期稳健发展的基础。" 以创新为核心发展驱动力 从复星医药近日发布的2025年半年报看，上半年公司实现营业收入195.14亿元；归母净利润为17.02亿 元，同比增长38.96%。 值得关注的是，上半年复星医药创新药品收入超43亿元，同比增长14.26%。公司半年报显示，创新产 品上市带来的产品结构优化和销售增长是报告期内业绩的主要驱动因素。复星医药通过自主研发、合作 开发、许可引进、基金孵化、产业投资等多元化、多层次的合作模式，推动创新技术和产品的开发和转 化落地。 报 ...

Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovation-driven enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from follower to leader [1] Group 1: Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit of 1.702 billion yuan, representing a year-on-year growth of 38.96% [1] - Revenue from innovative drugs exceeded 4.3 billion yuan, marking a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [2] Group 2: Innovation Strategy - The company emphasizes innovation as its core development engine, focusing on unmet clinical needs and core therapeutic areas, while enhancing R&D capabilities and efficiency [1][2] - Fosun Pharma has approved 4 innovative drugs and 57 generic drugs during the reporting period, with nearly 20 innovative drug clinical trials approved by regulatory agencies [2] Group 3: Global Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue, with a focus on establishing a commercial presence in the U.S. market [3] - The company has built a mature commercialization system, with over 1,000 personnel in its overseas commercialization team, and aims to deepen international cooperation [4] Group 4: Strategic Initiatives - Fosun Pharma plans to launch a new A+H share equity incentive plan, with core performance indicators focusing on net profit and innovative drug revenue [2] - The company adheres to the 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to accelerate progress in these areas [6]

国联民生（601456）证券股份有限公司研究员夏禹、郑薇9月2日发布研报《复星医药：经营稳健创新药 同比增长》称，维持复星医药"增持"评级。 中国经济网北京9月4日讯复星医药（600196）(600196.SH)今日收报29.33元，跌幅5.30%。 ...

Core Viewpoint - Fosun International reported a total revenue of 87.3 billion yuan for the first half of 2025, a year-on-year decrease of 10.8% [1] - The group's net profit attributable to shareholders was 660 million yuan, down 8.2% year-on-year [1] Revenue Breakdown - The revenue from the Happiness, Abundance, Health, and Intelligent Manufacturing segments decreased by 21.9%, increased by 3.3%, decreased by 3.0%, and decreased by 24.6%, respectively, totaling 33.72 billion, 27.83 billion, 22.57 billion, and 4.02 billion yuan [1] Insurance Sector Performance - Fosun Portugal Insurance achieved total premium income of 3.27 billion euros, up 16.5% year-on-year, with a market share of 29.3% [1] - The international business premium income was 920 million euros, up 4.3%, accounting for 28.2% of total premium income [2] - The net profit for Fosun Portugal Insurance was 133 million euros, an increase of 27.6% [1] Reinsurance and Health Insurance - Dingrui Reinsurance reported total premiums of 1.06 billion USD, a year-on-year increase of 25.1%, with a net profit of 90 million USD and a ROE of 13.4% [2] - Fosun United Health Insurance achieved total premium income of 3.64 billion yuan, up 31.1% year-on-year, with a net profit of 33 million yuan [2] Wealth Management and Technology - Fosun Wealth Holdings launched the FinRWA Platform, focusing on real-world asset technology and tokenization projects [3] - The team for Star Road Technology consists of professionals from major tech companies, enhancing operational efficiency and development quality [3] Pharmaceutical Sector - Fosun Pharma reported revenue of 19.426 billion yuan, with innovative drug revenue growing by 14.26% to over 4.3 billion yuan [4] - The net profit attributable to shareholders was 1.702 billion yuan, an increase of 38.94% [4] Subsidiary Performance - Yuyuan's revenue decreased by 30.68% to 19.112 billion yuan, with a net profit decline of 94.50% to 63 million yuan [4] - Fosun Tourism's revenue reached a historical high of 9.535 billion yuan, up 1.3% year-on-year, with an operating profit of 1.269 billion yuan, up 22.4% [4] Future Outlook - The company adjusted its revenue forecasts for 2025-2026 to 96 billion and 103.4 billion yuan, respectively, with net profit estimates of 730 million and 930 million yuan [5] - The EPS estimates for 2025-2026 are adjusted to 0.02 and 0.03 yuan, respectively [5]

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 芬太尼 | 0.65 | 兵装重组概念 | -7.44 | | BC电池 | 0.39 | 国产航母 | -5.45 | | 青蒿素 | 0.17 | 军工信息化 | -4.97 | | 光刻胶 | 0.10 | 成飞概念 | -4.76 | | 重组蛋白 | 0.03 | 军民融合 | -4.67 | | 石墨电极 | 0.02 | 大飞机 | -4.10 | | HJT电池 | -0.23 | 中船系 | -4.07 | | 光刻机 | -0.25 | 航空发动机 | -3.87 | | 减肥药 | -0.27 | 商业航天 | -3.71 | | 创新药 | -0.43 | 卫星导航 | -3.59 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.58亿元，其中，3股获主力资金净流入，净流入 资金居首的是百花医药，今日主力资金净流入1.09亿元，净流入资金居前的还有华润双鹤、浙江医药 等，主力资金分别净流入1416.28万元、579.44万元。 （原标题：青蒿素概念涨0.17 ...

Core Viewpoint - WuXi AppTec's revenue for the first half of 2025 was 106.3 million yuan, with sales of its CAR-T drug, Regiokyuran, amounting to 81 million yuan, which is lower than the sales figures from the same period in 2024 and 2023 [1][2]. Group 1: Company Performance - WuXi AppTec's CAR-T drug sales of 81 million yuan in the first half of 2025 were below the 86.8 million yuan in 2024 and 87.7 million yuan in 2023 [2]. - Legend Biotech reported a global sales figure of 439 million USD (approximately 3.1 billion yuan) for its CAR-T drug in Q2 2025, with total sales for the first half reaching 808 million USD (approximately 5.7 billion yuan), marking a year-on-year growth of 100% [4]. - Legend Biotech's CAR-T product, Carvykti, achieved sales of 4.39 billion yuan in Q2 2025, outperforming major competitors [18]. Group 2: Market Dynamics - The Chinese CAR-T market has seven approved products, with Legend Biotech's sales being significantly higher than its competitors, indicating a strong market presence [3]. - The high cost of CAR-T treatments remains a barrier to market penetration in China, with most patients unable to afford the treatment priced over one million yuan [29]. - The lack of a mature commercialization path for CAR-T products in China is a common challenge faced by companies in this sector [7]. Group 3: Regulatory and Insurance Landscape - Companies are attempting to improve payment capabilities for CAR-T treatments in China, with some products undergoing dual-line applications for basic medical insurance and commercial insurance [31]. - WuXi AppTec's Regiokyuran is priced at 1.29 million yuan, making it one of the most expensive CAR-T products in the market [28]. - The ongoing efforts to include CAR-T products in insurance coverage highlight the industry's struggle to balance pricing and accessibility for patients [30][34]. Group 4: Future Outlook - Legend Biotech's CEO anticipates the company will achieve profitability by 2026, indicating a positive outlook for future financial performance [20]. - The industry is exploring innovative production methods to reduce costs, with WuXi AppTec beginning to source key raw materials from domestic suppliers [35]. - The emergence of in-body CAR-T cell preparation technology may offer new avenues for cost reduction and accessibility in the future [36][37].

9月2日，复星医药子公司复宏汉霖（2696.HK）与Organon共同宣布，美国食品药品监督管理局 （FDA）已批准地舒单抗注射液（60mg/mL）BILDYOS®（denosumab-nxxp）和地舒单抗注射液 （120mg/1.7mL）BILPREVDA®（denosumab-nxxp）的上市申请。两款产品分别为PROLIA® （denosumab）和XGEVA®（denosumab）的生物类似药，此次获批覆盖原研产品在美国已获批的所有 适应症。 ...

Group 1 - Zhonglun New Materials plans to reduce its shareholding by up to 4 million shares, accounting for 1% of the total share capital [1] - Haojiang Intelligent plans to reduce its shareholding by up to 1.5 million shares, accounting for 0.8364% of the total share capital [1] - Dekeli plans to reduce its shareholding by up to 474,180 shares, accounting for 3% of the total share capital [1][2] Group 2 - Fosun Pharma's subsidiary has received FDA approval for its HLX14 injection, intended for treating osteoporosis in postmenopausal women [3][4] - Shengtai Group plans to reduce its shareholding by up to 16.67 million shares, accounting for 3% of the total share capital [5] - Fangyuan Co. plans to reduce its shareholding by up to 15.3 million shares, accounting for 3% of the total share capital [6] Group 3 - Shenkai Co. completed a tender offer, resulting in 14.5655 million shares being accepted, giving the acquirer a 9.71% stake [8] - Guangdong Construction's 90MW solar-storage project in Tibet has achieved full capacity grid connection [9] - Kesi Technology plans to reduce its shareholding by up to 471,220 shares, accounting for 3% of the total share capital [9] Group 4 - Zhongtai Automobile's subsidiary faces forced execution, impacting its operational capacity [10] - Weima Agricultural Machinery plans to reduce its shareholding by up to 960,000 shares, accounting for 0.98% of the total share capital [10] - Tianqi Co. signed a strategic cooperation agreement with EVE Energy to enhance the lithium battery supply chain [11] Group 5 - Sudavige plans to acquire up to 51% of Changzhou Weipu Semiconductor Equipment Co. for a total valuation of up to 1 billion yuan [12] - Dengyun Co. plans to transfer 75% of its subsidiary's equity for 137 million yuan [13] - Sierte has received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations [14] Group 6 - Enjie Co. received a VAT refund of 188 million yuan for its subsidiary [15] - Jiama Clothing plans to reduce its shareholding by up to 366,000 shares, accounting for 0.28238% of the total share capital [16] - Xinong Co. plans to reduce its shareholding by up to 1.05 million shares, accounting for 0.6737% of the total share capital [17] Group 7 - Jiewate plans to jointly acquire 66.25% of Xinguang Haian for a total price of 418 million yuan [18] - Hubei Energy reported an increase in power generation by 22.05% year-on-year in August, with a total of 5.020 billion kWh generated [19][20] - Nasda signed a strategic cooperation agreement with Teld for collaboration in market and product innovation [21] Group 8 - Jinli Technology plans to reduce its shareholding by up to 978,200 shares, accounting for 0.56% of the total share capital [22][23]